<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Karch CM</submitter><funding>NINDS NIH HHS</funding><pagination>1092-100</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3971727</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>113(5)</volume><pubmed_abstract>Amyotrophic lateral sclerosis is a progressively paralytic neurodegenerative disease that can be caused by mutations in Cu,Zn-superoxide dismutase 1 (SOD1). Transgenic mice that over-express mutant SOD1 develop paralysis and accumulate aggregates of mutant protein in the brainstem and spinal cord. The present study uses a cell culture model to demonstrate alpha B-crystallin is capable of reducing aggregation of mutant SOD1. To test the role of alpha B-crystallin in modulating SOD1 aggregation in vivo, alpha B-crystallin deficient mice were bred to mice expressing two different SOD1 mutants (G37R and L126Z). Although completely eliminating alpha B-crystallin reduced the interval to disease endstage by 20-30 days in mice expressing either mutant, there were no detectable changes in the level</pubmed_abstract><journal>Journal of neurochemistry</journal><pubmed_title>An examination of alpha B-crystallin as a modifier of SOD1 aggregate pathology and toxicity in models of familial amyotrophic lateral sclerosis.</pubmed_title><pmcid>PMC3971727</pmcid><funding_grant_id>P01 NS049134</funding_grant_id><funding_grant_id>NS044278</funding_grant_id><funding_grant_id>R01 NS044278</funding_grant_id><pubmed_authors>Karch CM</pubmed_authors><pubmed_authors>Borchelt DR</pubmed_authors></additional><is_claimable>false</is_claimable><name>An examination of alpha B-crystallin as a modifier of SOD1 aggregate pathology and toxicity in models of familial amyotrophic lateral sclerosis.</name><description>Amyotrophic lateral sclerosis is a progressively paralytic neurodegenerative disease that can be caused by mutations in Cu,Zn-superoxide dismutase 1 (SOD1). Transgenic mice that over-express mutant SOD1 develop paralysis and accumulate aggregates of mutant protein in the brainstem and spinal cord. The present study uses a cell culture model to demonstrate alpha B-crystallin is capable of reducing aggregation of mutant SOD1. To test the role of alpha B-crystallin in modulating SOD1 aggregation in vivo, alpha B-crystallin deficient mice were bred to mice expressing two different SOD1 mutants (G37R and L126Z). Although completely eliminating alpha B-crystallin reduced the interval to disease endstage by 20-30 days in mice expressing either mutant, there were no detectable changes in the level</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Jun</publication><modification>2025-04-04T01:27:15.502Z</modification><creation>2019-03-27T01:24:15Z</creation></dates><accession>S-EPMC3971727</accession><cross_references><pubmed>20067574</pubmed><doi>10.1111/j.1471-4159.2010.06572.x</doi></cross_references></HashMap>